Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a company with a promising future, as evidenced by their high sensitivity and specificity rates for cancer detection using their breakthrough Capture-Seq technology. With a potential application for multi-cancer early detection and treatment monitoring, VolitionRX could see significant market traction and valuation in the future. Along with positive clinical data and potential partnerships, VolitionRX's financials also look promising with a current market value of $190M and a DCF-based asset value of $201M for Nu.Q diagnostic tests. However, risks such as failure in clinical development, difficulties securing license agreements, and dilution risk should be considered when evaluating the company.

Bears say

VolitionRX is a company with a number of potential risks, including Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk. While the company has made some progress in terms of platform validation and securing partnerships, the recent reverse split and continued need for additional funding suggest that turning this progress into sustainable commercial success may prove challenging. Additionally, VolitionRX's financials are a cause for concern, with a low cash balance and consistent losses, factors that may make investors cautious.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jun 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.